An apparent hit in Nash has more than doubled the group’s market cap. But are the data all they seem?
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Novo Nordisk delays the full US launch of its obesity drug again, as Lilly breathes down its neck.
Hypoglycaemia rates raise doubts again.
The group gets a win in severe hypertriglyceridaemia, but a bigger readout in Nash awaits.